Ajou University Industry-Academic Cooperation Foundation

Gi Bang Koo

Yu Na Jo

You Sun Kim

You-Sun Kim

Woo Jung Kim

Jung Ho Yun

The present invention relates to a pharmaceutical composition for an anticancer adjuvant comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promotor or activator as an active ingredient. In addition, the present invention provides a method of promoting cancer cell apoptosis, characterized by co-administering an anticancer agent and a RIP3 protein expression promotor or activator to cancer cells. Also, the present invention relates to a method for screening an anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of an anticancer agent, and a method for monitoring sensitivity of an anticancer agent depending on the RIP3 expression. Accordingly, in the case of a patient lacking the expression of RIP3, it is expected to be an effective treatment strategy to pre-treat a demethylating agent to induce the expression of RIP3 and then to use a conventional chemotherapeutic agent. In addition, in chemotherapy, it is anticipated that the present invention may be an effective strategy in screening an anticancer adjuvant which monitors and enhances sensitivity of an anticancer agent.

Composition for anticancer adjuvant comprising RIP3 expression promoter as active ingredient, method for screening anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of anticancer agent, and method for monitoring sensitivity of anticancer agent

The present invention relates to a pharmaceutical composition for an anticancer adjuvant containing a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent or activator as an active ingredient. The present invention also provides a method for enhancing cancer cell death, comprising administering a RIP3 protein expression inducing agent or activator in combination with an anticancer drug to cancer cells. Additionally, the present invention relates to a method for screening an anticancer adjuvant which enhances anticancer drug sensitivity by promoting RIP3 expression; and a method for monitoring anticancer drug sensitivity based on RIP3 expression. Therefore, in the case of patients lacking RIP3 expression, the use of a conventional chemotherapeutic agent after inducing RIP3 expression by pretreatment with a demethylating agent may be an effective therapeutic strategy. Also, it is expected that monitoring anticancer drug sensitivity and screening an anticancer adjuvant that enhances anticancer drug sensitivity in anticancer therapy may be an effective strategy.

Anticancer adjuvant composition containing RIP3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting RIP3 expression, and method for monitoring sensitivity of anticancer drug

Growing community of inventors

Chungcheongnam-do, South Korea

Gi Bang Koo